[Towards the individualisation of prescriptions in oncology: urogenital cancers].
The daily management of urogenital cancers is currently based on prognostic classifications derived from the identification of independent clinical or biological indicators of overall survival. These classifications are used for patient stratification in clinical trials and definition of appropriate strategies according to prognostic groups. Their knowledge is therefore essential for optimizing treatment decisions. Metastatic germ cell tumours and renal cell cancers as well as localised prostate cancers are classical models for the development of such classifications. The emergence of targeted therapies and the identification of predictive parameters for treatment efficacy should represent a further step towards the emergence of individualized treatments in the near future.
Pouessel
Damien
D
Département d'oncologie médicale, CRLC Val-d'Aurelle, 34298 Montpellier Cedex 5.
Culine
Stéphane
S
D002292:Carcinoma, Renal Cell / Q000628:therapy; D006801:Humans; D007680:Kidney Neoplasms / Q000628:therapy; D008297:Male; D009373:Neoplasms, Germ Cell and Embryonal / Q000145:classification / Q000628:therapy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000628:therapy; D013736:Testicular Neoplasms / Q000145:classification / Q000628:therapy; D014565:Urogenital Neoplasms / Q000145:classification / Q000628:therapy*